Linked Life Data

2144449

Source:http://linkedlifedata.com/resource/pubmed/id/2144449

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1990-10-12
pubmed:abstractText
Monoclonal antibodies, either alone or as immunoconjugates, are now being utilized to treat patients with a wide range of hematologic malignancies. The aim of early studies was to delineate the feasibility of this form of therapy, assess toxicities, and identify potential obstacles. These trials demonstrated that MoABs can be safely administered, and that clinically significant and durable responses occur. Areas of future research include the development of more potent immunoconjugates, the study of MoABs in conjunction with other treatment modalities, and the evaluation of approaches that may eliminate the human anti-mouse antibody response. Methods using MoABs to block growth factor receptors or as vaccines are being considered. At present, MoAB therapy remains investigational and should be restricted to patients with diseases refractory to standard therapies. We are encouraged, however, by the therapeutic results witnessed in early Phase I/II trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0890-9091
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
77-84; discussion 84, 89-90, 92-3
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Monoclonal antibody therapy of lymphoproliferative disorders.
pubmed:affiliation
Northwestern University Medical School, Chicago, Illinois 60611.
pubmed:publicationType
Journal Article, Review